Molecular docking and oxidation kinetics of 3-phenyl coumarin derivatives by human CYP2A13

References

• Anttila S, Raunio H, Hakkola J. 2011. Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis. Am J Respir Cell Mol Biol. 44(5):583–590.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. 2000. The Protein Data Bank. Nucleic Acids Res. 28(1):235–242.
   PubMed Web of Science ®Google Scholar
• DeVore NM, Meneely KM, Bart AG, Stephens ES, Battaile KP, Scott EE. 2012. Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine. FEBS J. 279(9):1621–1631.
   PubMed Web of Science ®Google Scholar
• DeVore NM, Scott EE. 2012. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes. J Biol Chem. 287(32):26576–26585.
   PubMed Web of Science ®Google Scholar
• Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR. 1995. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet. 57(3):651–660.
   PubMed Web of Science ®Google Scholar
• Fukami T, Nakajima M, Sakai H, Katoh M, Yokoi T. 2007. CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos. 35(3):335–339.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Coughtrie M, Tukey RH. 2017. Drug metabolism. In: Bruton L, Lazo J, Parker K, editors. Goodman & Gilmans’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill; p. 85–100.
   Google Scholar
• Gundert-Remy U, Bernauer U, Blömeke B, Döring B, Fabian E, Goebel C, Hessel S, Jäckh C, Lampen A, Oesch F, et al. 2014. Extrahepatic metabolism at the body's internal-external interfaces. Drug Metab Rev. 46(3):291–324.
   PubMed Web of Science ®Google Scholar
• Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Lupyan D, Dahlgren MK, Knight JL, Kaus JW, et al. 2016. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput. 12(1):281–296.
   PubMed Web of Science ®Google Scholar
• He XY, Shen J, Ding X, Lu AY, Hong JY. 2004. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Drug Metab Dispos. 32(12):1516–1521.
   PubMed Web of Science ®Google Scholar
• He XY, Shen J, Hu WY, Ding X, Lu AY, Hong JY. 2004. Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. Arch Biochem Biophys. 427(2):143–153.
   PubMed Web of Science ®Google Scholar
• He XY, Tang L, Wang SL, Cai QS, Wang JS, Hong JY. 2006. Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int J Cancer. 118(11):2665–2671.
   PubMed Web of Science ®Google Scholar
• Hritz J, de Ruiter A, Oostenbrink C. 2008. Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking. J Med Chem. 51(23):7469–7477.
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Jacob P, Benowitz NL. 2005. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 57(1):79–115.
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Pelkonen O, Hakkola J, Raunio H. 2002. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol. 32(5):391–411.
   PubMed Web of Science ®Google Scholar
• Jacobson MP, Friesner RA, Xiang Z, Honig B. 2002. On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol. 320(3):597–608.
   PubMed Web of Science ®Google Scholar
• Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA. 2004. A hierarchical approach to all-atom protein loop prediction. Proteins. 55(2):351–367.
   PubMed Web of Science ®Google Scholar
• Jalas JR, Hecht SS, Murphy SE. 2005. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol. 18(2):95–110.
   PubMed Web of Science ®Google Scholar
• Ji M, Zhang Z, Li N, Xia R, Wang C, Yu Y, Yao S, Shen J, Wang SL. 2018. Identification of 5-hydroxymethylfurfural in cigarette smoke extract as a new substrate metabolically activated by human cytochrome P450 2A13. Toxicol Appl Pharmacol. 359:108–117.
   PubMed Web of Science ®Google Scholar
• Juvonen RO, Ahinko M, Huuskonen J, Raunio H, Pentikäinen OT. 2019. Development of new Coumarin-based profluorescent substrates for human cytochrome P450 enzymes. Xenobiotica. 49(9):1015–1024.
   PubMed Web of Science ®Google Scholar
• Juvonen RO, Ahinko M, Huuskonen J, Raunio H, Pentikäinen OT. Substrate selectivity of coumarin derivatives by human CYP1 enzymes: in vitro enzyme kinetics and in silico modelling. Submitted
   Google Scholar
• Juvonen RO, Kuusisto M, Fohrgrup C, Pitkänen MH, Nevalainen TJ, Auriola S, Raunio H, Pasanen M, Pentikäinen OT. 2016. Inhibitory effects and oxidation of 6-methylcoumarin, 7-methylcoumarin and 7-formylcoumarin via human CYP2A6 and its mouse and pig orthologous enzymes. Xenobiotica. 46(1):14–24.
   PubMed Web of Science ®Google Scholar
• Kinonen T, Pasanen M, Gynther J, Poso A, Järvinen T, Alhava E, Juvonen RO. 1995. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6. Br J Pharmacol. 116(6):2625–2630.
   PubMed Web of Science ®Google Scholar
• Korb O, Stützle T, Exner TE. 2009. Empirical scoring functions for advanced protein-ligand docking with plants. J Chem Inf Model. 49(1):84–96.
   PubMed Web of Science ®Google Scholar
• Lehtonen JV, Still DJ, Rantanen VV, Ekholm J, Björklund D, Iftikhar Z, Huhtala M, Repo S, Jussila A, Jaakkola J, et al. 2004. BODIL: a molecular modeling environment for structure–function analysis and drug design. J Comput Aided Mol Des. 18(6):401–419.
   PubMed Web of Science ®Google Scholar
• Li J, Abel R, Zhu K, Cao Y, Zhao S, Friesner RA. 2011. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins. 79(10):2794–2812.
   PubMed Web of Science ®Google Scholar
• Li L, Carratt S, Hartog M, Kovalchik N, Jia K, Wang Y, Zhang QY, Edwards P, Winkle LV, Ding X. 2017. Human CYP2A13 and CYP2F1 mediate naphthalene toxicity in the lung and nasal mucosa of CYP2A13/2F1-humanized mice. Environ Health Perspect. 125(6):067004.
   PubMed Web of Science ®Google Scholar
• Murphy SE, Raulinaitis V, Brown KM. 2005. Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos. 33(8):1166–1173.
   PubMed Web of Science ®Google Scholar
• Niinivehmas S, Postila PA, Rauhamäki S, Manivannan E, Kortet S, Ahinko M, Huuskonen P, Nyberg N, Koskimies P, Lätti S, et al. 2018. Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives. J Enzyme Inhib Med Chem. 33(1):743–754.
   PubMed Web of Science ®Google Scholar
• Oesch F, Fabian E, Landsiedel R. 2019. Xenobiotica-metabolizing enzymes in the lung of experimental animals, man and in human lung models. Arch Toxicol. 93(12):3419–3489.
   PubMed Web of Science ®Google Scholar
• Parkinson A, Ogilvie BW, Buckley DB, Kazmi F, Parkinson O. 2019. Biotransformation of xenobiotics. In: Casarett LJ, Doull J, Klaassen CD, editors. Casarett & Doull’s toxicology: the basic science of poisons. 9th ed. New York: McGraw Hill; p. 193–430.
   Google Scholar
• Pelkonen O, Raunio H. 1997. Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environmental Health Perspective Suppl. 105(Suppl 4):767–774.
   PubMed Web of Science ®Google Scholar
• Rauhamäki S, Postila PA, Niinivehmas S, Kortet S, Schildt E, Pasanen M, Manivannan E, Ahinko M, Koskimies P, Nyberg N, et al. 2018. Structure–activity relationship analysis of 3-phenylcoumarin-based monoamine oxidase B inhibitors. Front Chem. 6:41.
   PubMed Web of Science ®Google Scholar
• Raunio H, Rahnasto-Rilla M. 2012. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact. 27(2):73–88.
   PubMedGoogle Scholar
• Schrödinger. 2015. The PyMOL molecular graphics system, Version 2.3.
   Google Scholar
• Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M. 2007. Epik: a software program for pK( a ) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des. 21(12):681–691.
   PubMed Web of Science ®Google Scholar
• Sheng Y, Chen Y, Wang L, Liu G, Li W, Tang Y. 2014. Effects of protein flexibility on the site of metabolism prediction for CYP2A6 substrates. J Mol Graph Model. 54:90–99.
   PubMed Web of Science ®Google Scholar
• Shimada T, Takenaka S, Kakimoto K, Murayama N, Lim YR, Kim D, Foroozesh MK, Yamazaki H, Guengerich FP, Komori M. 2016. Structure–function studies of naphthalene, phenanthrene, biphenyl, and their derivatives in interaction with and oxidation by cytochromes P450 2A13 and 2A6. Chem Res Toxicol. 29 (6):1029–1040.
   PubMed Web of Science ®Google Scholar
• SIMCA. Umetrics. version 15.0.2. [accessed 2021 Feb 26]. https://www.sartorius.com/en/products/process-analytical-technology/data-analytics-software/mvda-software/simca?gclid=Cj0KCQiAst2BBhDJARIsAGo2ldWk7cPBO2Aqv6npSJGViHKYuCMGMo-H3K2DfuJ-i_hJKkfxdyFSFcgaAnuFEALw_wcB
   Google Scholar
• Smith BD, Sanders JL, Porubsky PR, Lushington GH, Stout CD, Scott EE. 2007. Structure of the human lung cytochrome P450 2A13. J Biol Chem. 282(23):17306–17313.
   PubMed Web of Science ®Google Scholar
• Su T, Ding X. 2004. Regulation of the cytochrome P450 2A genes. Toxicol Appl Pharmacol. 199(3):285–294.
   PubMed Web of Science ®Google Scholar
• von Weymarn LB, Murphy SE. 2003. CYP2A13-catalysed coumarin metabolism: comparison with CYP2A5 and CYP2A6. Xenobiotica. 33(1):73–81.
   PubMed Web of Science ®Google Scholar
• Word JM, Lovell SC, Richardson JS, Richardson DC. 1999. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol. 285(4):1735–1747.
   PubMed Web of Science ®Google Scholar
• Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF. 2005. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol. 12(9):822–823.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Zhang X, D'Agostino J, Wu H, Zhang QY, von Weymarn L, Murphy SE, Ding X. 2007. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther. 323(2):570–578.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yang X, Wang Y, Wang X, Lu H, Zhang X, Xiao X, Li S, Wang X, Wang SL. 2013. Cytochrome P450 2A13 is an efficient enzyme in metabolic activation of aflatoxin G1 in human bronchial epithelial cells. Arch Toxicol. 87(9):1697–1707.
   PubMed Web of Science ®Google Scholar